Dr. Jeffrey R. Jay, M.D.
Latest statistics and disclosures from Great Point Partners's latest quarterly 13F-HR filing:
- Top 5 stock holdings are AMLX, RZLT, NKTR, ZURA, SLNO, and represent 39.16% of Great Point Partners's stock portfolio.
- Added to shares of these 10 stocks: NKTR (+$17M), SLNO (+$15M), ASND (+$15M), APGE (+$12M), DNTH (+$11M), EPRX (+$7.1M), PHVS, IMVT, ORKA, ZURA.
- Started 12 new stock positions in NKTR, SLNO, CAPR, ABSI, HRMY, ASND, ORKA, DNTH, APGE, EPRX. SANA, PHVS.
- Reduced shares in these 10 stocks: ABVX (-$97M), IONS (-$28M), LEGN (-$7.7M), AKBA (-$7.2M), EOLS (-$6.6M), ACLX (-$6.6M), RZLT (-$5.5M), AMLX, KALV, CNTA.
- Sold out of its positions in AKBA, ACLX, CNTA, EOLS, KALV, PMN, SRRK, HLXB.
- Great Point Partners was a net seller of stock by $-73M.
- Great Point Partners has $243M in assets under management (AUM), dropping by 57.67%.
- Central Index Key (CIK): 0001281446
Tip: Access up to 7 years of quarterly data
Positions held by Dr. Jeffrey R. Jay, M.D. consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Great Point Partners
Great Point Partners holds 30 positions in its portfolio as reported in the September 2025 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Amylyx Pharmaceuticals (AMLX) | 9.5 | $23M | -15% | 1.7M | 13.59 |
|
| Rezolute (RZLT) | 9.5 | $23M | -19% | 2.5M | 9.40 |
|
| Nektar Therapeutics (NKTR) | 7.0 | $17M | NEW | 300k | 56.90 |
|
| Zura Bio (ZURA) | 6.8 | $17M | +20% | 3.8M | 4.33 |
|
| Soleno Therapeutics (SLNO) | 6.3 | $15M | NEW | 225k | 67.60 |
|
| Ascendis Pharma A S (ASND) | 6.1 | $15M | NEW | 75k | 198.81 |
|
| Abivax SA F (ABVX) | 5.3 | $13M | -88% | 150k | 84.90 |
|
| Apogee Therapeutics (APGE) | 5.0 | $12M | NEW | 304k | 39.73 |
|
| Dianthus Therapeutics (DNTH) | 4.3 | $11M | NEW | 266k | 39.35 |
|
| Cytokinetics (CYTK) | 3.4 | $8.2M | 150k | 54.96 |
|
|
| Immunovant (IMVT) | 3.3 | $8.1M | +90% | 500k | 16.12 |
|
| Xenon Pharmaceuticals (XENE) | 3.3 | $8.0M | 200k | 40.15 |
|
|
| Neurogene (NGNE) | 3.2 | $7.7M | -8% | 447k | 17.33 |
|
| Eupraxia Pharmaceuticals (EPRX) | 2.9 | $7.1M | NEW | 1.2M | 5.90 |
|
| Upstream Bio (UPB) | 2.3 | $5.6M | 300k | 18.81 |
|
|
| Jade Biosciences (JBIO) | 2.3 | $5.5M | +27% | 633k | 8.63 |
|
| Ionis Pharmaceuticals (IONS) | 2.2 | $5.2M | -84% | 80k | 65.42 |
|
| Akero Therapeutics (AKRO) | 2.0 | $4.9M | 104k | 47.48 |
|
|
| Taysha Gene Therapies (TSHA) | 2.0 | $4.9M | 1.5M | 3.27 |
|
|
| Context Therapeutics (CNTX) | 1.9 | $4.5M | 4.7M | 0.97 |
|
|
| Pharvaris N V (PHVS) | 1.6 | $3.9M | NEW | 155k | 24.95 |
|
| Dbv Technologies Sa (DBVT) | 1.6 | $3.8M | 379k | 10.00 |
|
|
| Legend Biotech 2 Adr Rep Ord (LEGN) | 1.5 | $3.7M | -67% | 114k | 32.61 |
|
| Oruka Therapeutics (ORKA) | 1.5 | $3.5M | NEW | 183k | 19.23 |
|
| Unicycive Therapeutics (UNCY) | 1.4 | $3.5M | 797k | 4.36 |
|
|
| Sana Biotechnology (SANA) | 1.0 | $2.5M | NEW | 700k | 3.55 |
|
| Absci Corp (ABSI) | 1.0 | $2.4M | NEW | 796k | 3.04 |
|
| Harmony Biosciences Hldgs In Call Option (HRMY) | 1.0 | $2.3M | NEW | 85k | 27.56 |
|
| Pliant Therapeutics (PLRX) | 0.5 | $1.3M | 850k | 1.48 |
|
|
| Capricor Therapeutics Put Option (CAPR) | 0.3 | $632k | NEW | 88k | 7.21 |
|
Past Filings by Great Point Partners
SEC 13F filings are viewable for Great Point Partners going back to 2013
- Great Point Partners 2025 Q3 filed Nov. 14, 2025
- Great Point Partners 2025 Q2 filed Aug. 14, 2025
- Great Point Partners 2025 Q1 filed May 15, 2025
- Great Point Partners 2024 Q4 filed Feb. 14, 2025
- Great Point Partners 2024 Q3 filed Nov. 13, 2024
- Great Point Partners 2024 Q2 filed Aug. 14, 2024
- Great Point Partners 2024 Q1 filed May 15, 2024
- Great Point Partners 2023 Q4 filed Feb. 14, 2024
- Great Point Partners 2023 Q3 filed Nov. 14, 2023
- Great Point Partners 2023 Q2 filed Aug. 14, 2023
- Great Point Partners 2023 Q1 filed May 15, 2023
- Great Point Partners 2022 Q4 filed Feb. 14, 2023
- Great Point Partners 2022 Q3 filed Nov. 14, 2022
- Great Point Partners 2022 Q2 filed Aug. 15, 2022
- Great Point Partners 2022 Q1 filed May 16, 2022
- Great Point Partners 2021 Q4 filed Feb. 14, 2022